— Onconova Therapeutics (NASDAQ: ONTX) reported FY2019 net
loss of $1.49 per share, vs. $4.99 per share last year.
— Net loss was $21.5 million compared to $20.4 million last
year.
— Research and development expenses were $15.5 million versus
$16.9 million for 2018.
— Cash and cash equivalents as of December 31, 2019,
totaled $22.7 million, compared to $17 million as of December 31, 2018.